These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1153 related articles for article (PubMed ID: 19323013)
1. Immunogenicity and safety of a DTaP-IPV//PRP-T vaccine (Pentaxim) booster during the second year of life in Thai children primed with an acellular pertussis combined vaccine. Thisyakorn U; Pancharoen C; Chuenkitmongkol S; Ortiz E Southeast Asian J Trop Med Public Health; 2009 Mar; 40(2):282-94. PubMed ID: 19323013 [TBL] [Abstract][Full Text] [Related]
2. One-year post-primary antibody persistence and booster immune response to a fully liquid five-component acellular pertussis, diphtheria, tetanus, inactivated poliomyelitis, Haemophilus influenzae type b conjugate vaccine. Lin TY; Wang YH; Huang YC; Chiu CH; Lin PY; Chen CJ; Chavand P; Ortiz E Int J Infect Dis; 2007 Nov; 11(6):488-95. PubMed ID: 17349809 [TBL] [Abstract][Full Text] [Related]
3. Antibody persistence after a primary series of a new DTaP-IPV-Hep B-PRP-T combined vaccine or separate DTaP-IPV//PRP-T and hepatitis B vaccines at 2, 4, and 6 months of age and the effect of a subsequent DTaP-IPV//PRP-T booster vaccination at 18 months of age in healthy Argentinean infants. Tregnaghi M; Zambrano B; Santos-Lima E Pediatr Infect Dis J; 2012 Jan; 31(1):e24-30. PubMed ID: 22157567 [TBL] [Abstract][Full Text] [Related]
4. A fully liquid diphtheria-tetanus-five component acellular pertussis-inactivated poliomyelitis--Haemophilus influenzae type b conjugate vaccine: immunogenicity and safety of primary vaccination in Taiwanese infants. Lin TY; Wang YH; Chang LY; Huang YC; Kao HT; Lin PY; Lu HK; Chavand P; Ortiz E Int J Infect Dis; 2007 Mar; 11(2):129-36. PubMed ID: 16762579 [TBL] [Abstract][Full Text] [Related]
5. Antibody persistence after primary and booster doses of a pentavalent vaccine against diphtheria, tetanus, acellular pertussis, inactivated poliovirus, haemophilus influenzae type B vaccine among Thai children at 18-19 months of age. Chotpitayasunondh T; Thisyakorn U; Pancharoen C; Chuenkitmongkol S; Ortiz E Southeast Asian J Trop Med Public Health; 2012 Mar; 43(2):442-54. PubMed ID: 23082595 [TBL] [Abstract][Full Text] [Related]
6. Antibody persistence at 18-20 months of age and safety and immunogenicity of a booster dose of a combined DTaP-IPV//PRP∼T vaccine compared to separate vaccines (DTaP, PRP∼T and IPV) following primary vaccination of healthy infants in the People's Republic of China. Li RC; Li FX; Li YP; Hou QM; Li CG; Li YN; Chen FS; Hu XZ; Su WB; Zhang SM; Fang HH; Ye Q; Zeng TD; Liu TX; Li XB; Huang YN; Deng ML; Zhang YP; Ortiz E Vaccine; 2011 Nov; 29(50):9337-44. PubMed ID: 22001281 [TBL] [Abstract][Full Text] [Related]
7. Immunogenicity and safety of a pentavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type B conjugate combination vaccine (Pentaxim) with hepatitis B vaccine. Dutta AK; Verghese VP; Pemde HK; Mathew LG; Ortiz E Indian Pediatr; 2009 Nov; 46(11):975-82. PubMed ID: 19955579 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of an acellular pertussis, diphtheria, tetanus, inactivated poliovirus, Hib-conjugate combined vaccine (Pentaxim) at 2, 4, and 6 months of age plus hepatitis B vaccine at birth, 2, and 6 months of age in infants in Thailand. Thisyakorn U; Chotpitayasunondh T; Pancharoen C; Chuenkitmongkol S; Ortiz E Southeast Asian J Trop Med Public Health; 2010 Mar; 41(2):450-62. PubMed ID: 20578530 [TBL] [Abstract][Full Text] [Related]
9. Long-term immunogenicity assessment of a DTaP-IPV//PRP-T vaccine given at 2, 4, 6 and 18-19 months of age, and immunogenicity and safety of a DTaP-IPV vaccine given as a booster dose at 4 to 6 years of age in Thai children. Pancharoen C; Chotpitayasunondh T; Chuenkitmongkol S; Ortiz E Southeast Asian J Trop Med Public Health; 2012 May; 43(3):687-98. PubMed ID: 23077849 [TBL] [Abstract][Full Text] [Related]
10. A fully liquid DTaP-IPV-Hep B-PRP-T hexavalent vaccine for primary and booster vaccination of healthy Mexican children. Aquino AG; Brito MG; Doniz CE; Herrera JF; Macias M; Zambrano B; Plennevaux E; Santos-Lima E Vaccine; 2012 Oct; 30(45):6492-500. PubMed ID: 22863658 [TBL] [Abstract][Full Text] [Related]
11. Immunogenicity, reactogenicity and safety of a 7-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a DTPa-HBV-IPV/Hib combination vaccine in healthy infants. Knuf M; Habermehl P; Cimino C; Petersen G; Schmitt HJ Vaccine; 2006 May; 24(22):4727-36. PubMed ID: 16616973 [TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of a hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine at 2, 3, 4, and 12-14 months of age. Halperin SA; Tapiero B; Diaz-Mitoma F; Law BJ; Hoffenbach A; Zappacosta PS; Radley D; McCarson BJ; Martin JC; Brackett LE; Boslego JW; Hesley TM; Bhuyan PK; Silber JL Vaccine; 2009 Apr; 27(19):2540-7. PubMed ID: 19124057 [TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of a pentavalent vaccine compared with separate administration of licensed equivalent vaccines in US infants and toddlers and persistence of antibodies before a preschool booster dose: a randomized, clinical trial. Guerra FA; Blatter MM; Greenberg DP; Pichichero M; Noriega FR; Pediatrics; 2009 Jan; 123(1):301-12. PubMed ID: 19117896 [TBL] [Abstract][Full Text] [Related]
14. One-year post-primary antibody persistence and booster immune response to a DTaP-IPV//PRP~T vaccine (Pentaxim) given at 18 - 19 months of age in South African children primed at 6, 10 and 14 weeks of age with the same vaccine. Madhi SA; Cutland C; Jones S; Groome M; Ortiz E S Afr Med J; 2011 Nov; 101(12):879-83. PubMed ID: 22273029 [TBL] [Abstract][Full Text] [Related]
15. Booster immunization with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate combination vaccine in the second year of life: safety, immunogenicity and persistence of antibody responses. Heininger U; ; ; Sänger R; Jacquet JM; Schuerman L Vaccine; 2007 Jan; 25(6):1055-63. PubMed ID: 17049692 [TBL] [Abstract][Full Text] [Related]
16. Interchangeability of two diphtheria and tetanus toxoids, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b conjugate vaccines as a fourth dose in 15-20-month-old toddlers. Halperin SA; Tapiero B; Law B; Diaz-Mitoma F; Duval B; Langley JM; Elrick DB; Jacquet JM Vaccine; 2006 May; 24(18):4017-23. PubMed ID: 16516357 [TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and reactogenicity of primary immunization with a hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type B vaccine coadministered with two doses of a meningococcal C-tetanus toxoid conjugate vaccine. Tejedor JC; Moro M; Ruiz-Contreras J; Castro J; Gómez-Campderá JA; Navarro ML; Merino JM; Martín-Ancel A; Roca J; García-del-Río M; Jurado A; Díez-Delgado FJ; Omeñaca F; García-Sicilia J; Boceta R; García-Corbeira P; Jacquet JM; Collard A; Schuerman L; Pediatr Infect Dis J; 2006 Aug; 25(8):713-20. PubMed ID: 16874171 [TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and safety study of a new DTaP-IPV-Hep B-PRP-T combined vaccine compared to a licensed DTaP-IPV-Hep B//PRP-T comparator, both concomitantly administered with a 7-valent pneumococcal conjugate vaccine at 2, 4, and 6 months of age in Thai infants. Kosalaraksa P; Thisyakorn U; Benjaponpitak S; Chokephaibulkit K; Santos-Lima E Int J Infect Dis; 2011 Apr; 15(4):e249-56. PubMed ID: 21334243 [TBL] [Abstract][Full Text] [Related]
19. Concomitant use of the 3-dose oral pentavalent rotavirus vaccine with a 3-dose primary vaccination course of a diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type b vaccine: immunogenicity and reactogenicity. Ciarlet M; He S; Lai S; Petrecz M; Yuan G; Liu GF; Mikviman E; Heaton PM; Panzer F; Rose T; Koller DY; Van Damme P; Schödel F Pediatr Infect Dis J; 2009 Mar; 28(3):177-81. PubMed ID: 19209092 [TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and safety of a combination diphtheria, tetanus toxoid, acellular pertussis, hepatitis B, and inactivated poliovirus vaccine coadministered with a 7-valent pneumococcal conjugate vaccine and a Haemophilus influenzae type b conjugate vaccine. Pichichero ME; Bernstein H; Blatter MM; Schuerman L; Cheuvart B; Holmes SJ; J Pediatr; 2007 Jul; 151(1):43-9, 49.e1-2. PubMed ID: 17586189 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]